Impartial Study Displays 97 Percent of Vivos People Reached Their Desired Procedure Final result

HIGHLANDS RANCH, Colo., July 07, 2021 (Globe NEWSWIRE) — Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a healthcare engineering business focused on establishing and commercializing revolutionary diagnostic and treatment modalities for people struggling from rest-disordered respiration, which include mild-to-average obstructive slumber apnea (OSA), now announced that the Firm has unveiled new data from an impartial individual survey associated to its proprietary Vivos therapy for managing dental tissue anomalies and dentofacial malformations acknowledged to be linked with OSA and other debilitating wellbeing ailments.

Vital conclusions incorporate:

  • Nearly all (97 %) of people surveyed explained that they experienced reached their wanted final result from the Vivos treatment method for their OSA.

  • More than 50 percent (63 per cent) of sufferers surveyed explained that they rely on the suggestions of their dentist to obtain a long lasting resolution that addresses the root result in of their OSA.

  • Virtually one-third (29 per cent) of clients surveyed reported that they searched for non-surgical possibilities to current criteria of treatment for treating OSA.

“Patients are the final arbiter of regardless of whether a specific therapy modality has obtained its ideal results,” mentioned Kirk Huntsman, Vivos Chairman and CEO. “This survey reaffirms that patients are in dire want of a remedy for their OSA – just one that is non-surgical, non-invasive, non-pharmaceutical and small-value – and that’s just the market area of interest that the Vivos treatment method fills. The actuality that practically all sufferers surveyed reported that they experienced accomplished their preferred treatment method result is a highly effective testimony about their scientific and cosmetic final results. Our technology just works.”

The sought after result for lots of Vivos people is frequently a substantial reduction in OSA and linked signs or symptoms, as affected person satisfaction and compliance prices with CPAP keep on being dismal. Some research demonstrate only 30 to 60 per cent CPAP adherence, and when left untreated OSA’s underlying disorders can develop into continual comorbidities, some of which might be life threatening. In distinction, the Vivos cure is typically accomplished in approximately 12 to 24 months, immediately after which most clients no for a longer time involve ongoing intervention.

Methodology:
Commissioned by Vivos, The EyeDeas Corporation, an independent investigate business, made the research and analyzed the data received from 123 anonymous individuals from 21 impartial Vivos-qualified clinicians residing in a number of marketplaces in the U.S., in regards to the use and effects of the Vivos procedure for addressing dental tissue anomalies and dentofacial malformations. Fieldwork was executed in June, 2021.

About Vivos Therapeutics, Inc.
Vivos Therapeutics Inc. (NASDAQ: VVOS) is a healthcare technological innovation enterprise focused on developing and commercializing innovative diagnostic and therapy modalities for adult sufferers struggling from sleep-disordered respiratory, together with obstructive sleep apnea (OSA). The Vivos procedure for gentle-to-average OSA consists of a custom-made oral equipment and protocols termed the Vivos Process. Vivos believes that its Vivos Process oral appliance technology signifies the very first clinically productive non-surgical, non-invasive, non-pharmaceutical and value-powerful resolution for persons with mild-to-average OSA. Vivos also sells orthodontic appliances for older people and young children. Vivos’ oral appliances have tested successful in in excess of 17,000 clients around the world by a lot more than 1,200 dentists. Combining systems and protocols that change the measurement, form, and position of the tissues of a patient’s higher airway, the Vivos Method opens airway house and might considerably decrease signs or symptoms and problems involved with delicate-to-moderate OSA, these as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes VivosScore, driven by the SleepImage diagnostic technology for Household Sleep Tests in grownups and youngsters. The Vivos Integrated Follow (VIP) program delivers dentists teaching and other price-extra companies in connection with applying the Vivos Procedure.

For a lot more info, pay a visit to www.vivoslife.com.

Cautionary Take note Concerning Forward-On the lookout Statements
This press release and statements of the Company’s management made in relationship therewith incorporate “forward-seeking statements” (as described in Segment 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Exchange Act of 1934, as amended) regarding potential functions, significantly with respect to the general public supplying explained herein. Text such as “may”, “should”, “expects”, “projects,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates” and versions of these kinds of terms and similar expressions are meant to determine forward-hunting statements. These statements include recognized and unidentified pitfalls and are dependent upon quite a few assumptions and estimates, which are inherently topic to considerable uncertainties and contingencies, numerous of which are beyond Vivos’ regulate. True effects (like the predicted added benefits of the Company’s technologies as explained herein) may well differ materially from all those expressed or implied by these ahead-searching statements. Factors that could trigger actual final results to differ materially contain, but are not restricted to, the danger components described in Vivos’ filings with the Securities and Trade Fee (“SEC”). Vivos’ filings can be attained free of charge of charge on the SEC’s website at www.sec.gov. Except to the extent essential by law, Vivos expressly disclaims any obligations or enterprise to release publicly any updates or revisions to any forward-looking statements contained herein to mirror any adjust in Vivos’ expectations with respect thereto or any transform in gatherings, conditions, or instances on which any statement is based.

Investor Relations Contact:
Edward Loew
Trader Relations Officer
(602) 903-0095
ed@vivoslife.com

Media Relations Get hold of:
Caitlin Kasunich / Jenny Robles
KCSA Strategic Communications
(212) 896-1241 / (212) 896-1231
ckasunich@kcsa.com / jrobles@kcsa.com